ArticleBlood research2018

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent.

Naohiro Sekiguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.